Established Safety Profile

The safety of YONDELIS^® was evaluated in 755 patients

YONDELIS^® was studied in 6 open-label, single-arm trials, in which 377 patients received YONDELIS^®, and 1 open-label, randomized, active-controlled clinical trial, in which 378 patients received YONDELIS^®. In these trials, 26% (197) of patients were treated with YONDELIS^® for 6 months or longer, and 8% (57) were treated with YONDELIS^® for 1 year or longer.¹

Incidence of selected treatment-emergent laboratory abnormalities in a pivotal trial^*¹

Laboratory Abnormalities	YONDELIS^®		Dacarbazine
Laboratory Abnormalities	All Grades (%)	Grades 3-4 (%)	All Grades (%)	Grades 3-4 (%)
Chemistry
Increased ALT	90	31	33	0.6
Increased AST	84	17	32	1.2
Increased ALP	70	1.6	60	0.6
Hypoalbuminemia	63	3.7	51	3.0
Increased creatinine	46	4.2	29	1.2
Increased CPK	33	6.4	9	0.6
Hyperbilirubinemia	13	1.9	5	0.6
Hematology
Anemia	96	19	79	12
Neutropenia	66	43	47	26
Thrombocytopenia	59	21	57	20

Laboratory Abnormalities	YONDELIS^®
Laboratory Abnormalities	All Grades (%)	Grades 3-4 (%)
Chemistry
Increased ALT	90	31
Increased AST	84	17
Increased alkaline phosphatase	70	1.6
Hypoalbuminemia	63	3.7
Increased creatinine	46	4.2
Increased creatine phosphokinase	33	6.4
Hyperbilirubinemia	13	1.9
Hematology
Anemia	96	19
Neutropenia	66	43
Thrombocytopenia	59	21
Laboratory Abnormalities	Dacarbazine
Laboratory Abnormalities	All Grades (%)	Grades 3-4 (%)
Chemistry
Increased ALT	33	0.6
Increased AST	32	1.2
Increased alkaline phosphatase	60	0.6
Hypoalbuminemia	51	3.0
Increased creatinine	29	1.2
Increased creatine phosphokinase	9	0.6
Hyperbilirubinemia	5	0.6
Hematology
Anemia	79	12
Neutropenia	47	26
Thrombocytopenia	57	20

ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatine phosphokinase.

^*Treatment-emergent laboratory abnormalities included those higher in the trabectedin arm compared with the dacarbazine arm by ≥5% (all grades) or by ≥2% (Grades 3-4). Incidence based on number of patients who had both baseline and at least 1 on-study laboratory measurement.

YONDELIS^® group (range: 373 to 377 patients) and dacarbazine group (range: 166 to168 patients).

Read about the efficacy of YONDELIS^®.

Adverse reactions reported in the pivotal trial

Selected adverse reactions^† occurring in ≥10% of patients receiving YONDELIS^® and at a higher incidence than in the control arm in the pivotal trial^‡1

System Organ Class	YONDELIS^® (N=378)		Dacarbazine (N=172)
Adverse Reaction	All Grades (%)	Grades 3-4 (%)	All Grades (%)	Grades 3-4 (%)
Gastrointestinal disorders
Nausea	75	7	50	1.7
Vomiting	46	6	22	1.2
Constipation	37	0.8	31	0.6
Diarrhea	35	1.6	23	0
General disorders and administration-site conditions
Fatigue^§	69	8	52	1.7
Peripheral edema	28	0.8	13	0.6
Metabolism and nutrition disorders
Decreased appetite	37	1.9	21	0.6
Respiratory, thoracic, and mediastinal disorders
Dyspnea	25	4.2	20	1.2
Nervous system disorders
Headache	25	0.3	19	0
Musculoskeletal and connective tissue disorders
Arthralgia	15	0	8	1.2
Myalgia	12	0	6	0
Psychiatric disorders
Insomnia	15	0.3	9	0

System Organ Class	YONDELIS^® (N=378)
Adverse Reaction	All Grades^b (%)	Grades 3-4 (%)
Gastrointestinal disorders
Nausea	75	7
Vomiting	46	6
Constipation	37	0.8
Diarrhea	35	1.6
General disorders and administration site conditions
Fatigue^§	69	8
Peripheral edema	28	0.8
Metabolism and nutrition disorders
Decreased appetite	37	1.9
Respiratory, thoracic, and mediastinal disorders
Dyspnea	25	4.2
Nervous system disorders
Headache	25	0.3
Musculoskeletal and connective tissue disorders
Arthralgia	15	0
Myalgia	12	0
Psychiatric disorders
Insomnia	15	0.3
System Organ Class	Dacarbazine (N=172)
Adverse Reaction	All Grades (%)	Grades 3-4 (%)
Gastrointestinal disorders
Nausea	50	1.7
Vomiting	22	1.2
Constipation	31	0.6
Diarrhea	23	0
General disorders and administration site conditions
Fatigue^§	52	1.7
Peripheral edema	13	0.6
Metabolism and nutrition disorders
Decreased appetite	21	0.6
Respiratory, thoracic and mediastinal disorders
Dyspnea	20	1.2
Nervous system disorders
Headache	19	0
Musculoskeletal and connective tissue disorders
Arthralgia	8	1.2
Myalgia	6	0
Psychiatric disorders
Insomnia	9	0

†Limited to adverse reactions occurring at a rate of ≥10% in the trabectedin arm and at a rate higher in the trabectedin arm compared with the dacarbazine arm by ≥5% in overall incidence or by ≥2% for Grades 3-4 adverse reactions.

‡Toxicity grade is based on National Cancer Institute common toxicity criteria, version 4.0.

§Fatigue is a composite of the following adverse event terms: fatigue, asthenia, and malaise.

Read about the efficacy of YONDELIS^®.

Reference:

YONDELIS^® (trabectedin) [package insert]. Horsham, PA: Janssen Products, LP; 2017.

CONTRAINDICATIONS — YONDELIS^® (trabectedin) is contraindicated in patients with known severe hypersensitivity, including anaphylaxis, to trabectedin.

WARNINGS AND PRECAUTIONS

Neutropenic sepsis, including fatal cases, can occur. In Trial 1, the incidence of Grade 3 or 4 neutropenia, based on laboratory values, was 43% (161/378). Median time to the first occurrence of Grade 3 or 4 neutropenia was 16 days (range: 8 days to 9.7 months). Median time to complete resolution of neutropenia was 13 days (range: 3 days to 2.3 months). Febrile neutropenia (fever ≥38.5°C with Grade 3 or 4 neutropenia) occurred in 18 patients (5%). Ten patients (2.6%) experienced neutropenic sepsis, 5 of whom had febrile neutropenia, which was fatal in 4 patients (1.1%). Assess neutrophil count prior to administration of each dose of YONDELIS^® and periodically throughout the treatment cycle. Withhold YONDELIS^® for neutrophil counts of less than 1500 cells/microliter on the day of dosing. Permanently reduce the dose of YONDELIS^® for life-threatening or prolonged, severe neutropenia in the preceding cycle.

Rhabdomyolysis — YONDELIS^® can cause rhabdomyolysis and musculoskeletal toxicity. In Trial 1, rhabdomyolysis leading to death occurred in 3 (0.8%) of the 378 patients. Elevations in creatine phosphokinase (CPK) occurred in 122 (32%) of the 378 patients receiving YONDELIS^®, including Grade 3 or 4 CPK elevation in 24 patients (6%), compared to 15 (9%) of the 172 patients receiving dacarbazine with any CPK elevation, including 1 patient (0.6%) with Grade 3 CPK elevation. Among the 24 patients receiving YONDELIS^® with Grade 3 or 4 CPK elevation, renal failure occurred in 11 patients (2.9%); rhabdomyolysis with the complication of renal failure occurred in 4 of these 11 patients (1.1%). Median time to first occurrence of Grade 3 or 4 CPK elevations was 2 months (range: 1 to 11.5 months). Median time to complete resolution was 14 days (range: 5 days to 1 month). Assess CPK levels prior to each administration of YONDELIS^®. Withhold YONDELIS^® for serum CPK levels more than 2.5 times the upper limit of normal. Permanently discontinue YONDELIS^® for rhabdomyolysis.

Hepatotoxicity, including hepatic failure, can occur. Patients with serum bilirubin levels above the upper limit of normal or AST or ALT levels >2.5 × ULN were not enrolled in Trial 1. In Trial 1, the incidence of Grade 3-4 elevated liver function tests (defined as elevations in ALT, AST, total bilirubin, or alkaline phosphatase) was 35% (134/378). Median time to development of Grade 3-4 elevation in ALT or AST was 29 days (range: 3 days to 11.5 months). Of the 134 patients with Grade 3 to 4 elevations in LFTs, 114 (85%) experienced complete resolution with the median time to complete resolution of 13 days (range: 4 days to 4.4 months). In Trial 1, the incidence of drug-induced liver injury (defined as concurrent elevation in ALT or AST of more than three times the upper limit of normal, alkaline phosphatase less than two times the upper limit of normal, and total bilirubin at least two times the upper limit of normal) was 1.3% (5/378). ALT or AST elevation greater than eight times the ULN occurred in 18% (67/378) of patients. Assess LFTs prior to each administration of YONDELIS^®and as clinically indicated based on underlying severity of pre‑existing hepatic impairment. Manage elevated LFTs with treatment interruption, dose reduction, or permanent discontinuation based on severity and duration of LFT abnormality.

Cardiomyopathy, including cardiac failure, congestive heart failure, ejection fraction decreased, diastolic dysfunction, or right ventricular dysfunction can occur. In Trial 1, patients with a history of New York Heart Association Class II to IV heart failure or abnormal left ventricular ejection fraction (LVEF) at baseline were ineligible. In Trial 1, cardiomyopathy occurred in 23 patients (6%) receiving YONDELIS^® and in four patients (2.3%) receiving dacarbazine. Grade 3 or 4 cardiomyopathy occurred in 15 patients (4%) receiving YONDELIS^® and 2 patients (1.2%) receiving dacarbazine; cardiomyopathy leading to death occurred in 1 patient (0.3%) receiving YONDELIS^® and in none of the patients receiving dacarbazine. The median time to development of Grade 3 or 4 cardiomyopathy in patients receiving YONDELIS^® was 5.3 months (range: 26 days to 15.3 months). Assess left ventricular ejection fraction (LVEF) by echocardiogram or multigated acquisition (MUGA) scan before initiation of YONDELIS^® and at 2- to 3-month intervals thereafter until YONDELIS^® is discontinued. Withhold YONDELIS^® for LVEF below lower limit of normal. Permanently discontinue YONDELIS^® for symptomatic cardiomyopathy or persistent left ventricular dysfunction that does not recover to lower limit of normal within 3 weeks.

Capillary Leak Syndrome (CLS) characterized by hypotension, edema, and hypoalbuminemia has been reported with YONDELIS^®, including serious CLS resulting in death. Monitor for signs and symptoms of CLS. Discontinue YONDELIS^® and promptly initiate standard management for patients with CLS, which may include a need for intensive care.

Extravasation Resulting in Tissue Necrosis — Extravasation of YONDELIS^®, resulting in tissue necrosis requiring debridement, can occur. Evidence of tissue necrosis can occur more than 1 week after the extravasation. There is no specific antidote for extravasation of YONDELIS^®. Administer YONDELIS^® through a central venous line.

Embryofetal Toxicity — Based on its mechanism of action, YONDELIS^® can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during therapy and for at least 2 months after the last dose of YONDELIS^®. Advise males with female partners of reproductive potential to use effective contraception during therapy and for at least 5 months after the last dose of YONDELIS^®.

Adverse Reactions — The most common (≥20%) adverse reactions are nausea (75%), fatigue (69%), vomiting (46%), constipation (37%), decreased appetite (37%), diarrhea (35%), peripheral edema (28%), dyspnea (25%), and headache (25%).

The most common (≥5%) grades 3-4 laboratory abnormalities are: neutropenia (43%), increased ALT (31%), thrombocytopenia (21%), anemia (19%), increased AST (17%), and increased creatine phosphokinase (6.4%).

DRUG INTERACTIONS

Effect of Cytochrome CYP3A Inhibitors — Avoid using strong CYP3A inhibitors (e.g., oral ketoconazole, itraconazole, posaconazole, voriconazole, clarithromycin, telithromycin, indinavir, lopinavir, ritonavir, boceprevir, nelfinavir, saquinavir, telaprevir, nefazodone, conivaptan) in patients taking YONDELIS^®. If a strong CYP3A inhibitor for short-term use (i.e., less than 14 days) must be used, administer the strong CYP3A inhibitor 1 week after the YONDELIS^® infusion, and discontinue it the day prior to the next YONDELIS^® infusion.

Effect of Cytochrome CYP3A Inducers — Avoid using strong CYP3A inducers (e.g., rifampin, phenobarbital, St. John's wort) in patients taking YONDELIS^®.

Please see full Prescribing Information for YONDELIS^®.

072957-170515

Established Safety Profile

The safety of YONDELIS^® was evaluated in 755 patients

Incidence of selected treatment-emergent laboratory abnormalities in a pivotal trial^*¹

Adverse reactions reported in the pivotal trial

Indication

Important Safety Information

YOU ARE NOW LEAVING YONDELIS.COM

Established Safety Profile

The safety of YONDELIS® was evaluated in 755 patients

Incidence of selected treatment-emergent laboratory abnormalities in a pivotal trial*1

Adverse reactions reported in the pivotal trial

YOU ARE NOW LEAVING YONDELIS.COM

The safety of YONDELIS^® was evaluated in 755 patients

Incidence of selected treatment-emergent laboratory abnormalities in a pivotal trial^*¹